A multi-institutional team has added more than 20 pathogens to the list of known bacteria that express the capsule polysaccharide poly-N-acetylglucosamine. The findings open up new indications for Alopexx Vaccine and Alopexx Pharmaceuticals, which are developing a vaccine and an antibody for passive immunization, respectively.